Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.

GUIDELINE TITLE
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.

BIBLIOGRAPHIC SOURCE(S)
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda (MD): Department of Health and Human Services (DHHS); 2009 Dec 1. 161 p.

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda (MD): Department of Health and Human Services (DHHS); 2008 Nov 3. 139 p. [558 references]

These guidelines generally represent the state of knowledge regarding the use of antiretroviral agents. However, as the science rapidly evolves, the availability of new agents and new clinical data may rapidly change therapeutic options and preferences. The guidelines, therefore, are updated frequently by the Panel and are available as a "living document" at the http://www.aidsinfo.nih.gov Web site.

Status information regarding this guideline is available from the AIDSinfo Web site, telephone (800) 448-0440, fax (301) 519-6616; TTY (888) 480-3739.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

January 29, 2010 - Videx (didanosine): The U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients about a rare, but serious, complication in the liver known as non-cirrhotic portal hypertension in patients using Videx or Videx EC (didanosine), a medication used to treat human immunodeficiency virus (HIV) infection. Because of the potential severity of portal hypertension, including death from hemorrhaging esophageal varices, FDA has revised the Warning and Precautions section of the didanosine drug label to assure safe use of the medication.
December 3, 2009 - Lexiva (fosamprenavir): GlaxoSmithKline and the U.S. Food and Drug Administration (FDA) notified healthcare professionals of modifications to the existing Warnings and Precautions section of the Prescribing Information including notification that increases in cholesterol have occurred with treatment, new emphasis on lipids management, and a recommendation that triglyceride and cholesterol testing be performed prior to initiating therapy with LEXIVA and at periodic intervals during therapy.
August 27, 2009 - Intelence (etravirine): Tibotec Therapeutics and the U.S. Food and Drug Administration (FDA) notified healthcare professionals of revisions to the WARNINGS AND PRECAUTIONS section of the prescribing information for Intelence (etravirine).
COMPLETE SUMMARY

abrir aquí para acceder al documento NGC AHRQ completo:
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.